Veracyte, Inc. (VCYT) Company Overview

What does Veracyte do?

Veracyte, Inc. is a Nasdaq-listed cancer diagnostics company. Its molecular tests translate tumor biology into clinical decisions: whether surgery may be avoided, whether treatment should be intensified, or whether recurrence risk requires monitoring. Physicians order U.S. laboratory-developed tests, while Veracyte bills insurers, Medicare, Medicaid, institutions, or patients; internationally, it also sells in-vitro diagnostic kits.

The portfolio spans prostate, thyroid, breast, bladder, and lung cancer. Decipher Prostate and Afirma are the scaled commercial franchises; Prosigna supports breast-cancer prognosis, Decipher Bladder informs bladder-cancer treatment, and TrueMRD extends the platform into minimal residual disease. Veracyte’s official company overview frames the mission as transforming cancer care worldwide.

How does Veracyte make money?

Veracyte reports one operating segment but three revenue types. Testing revenue is recognized when a patient report reaches the physician. Product revenue is mainly Prosigna and related IVD kits sold to laboratories. Biopharmaceutical and other revenue includes collaborations and contract services, but became immaterial after the Veracyte SAS wind-down.

Why is reimbursement the economic engine?

The physician orders the test, but the payer determines whether it becomes collectible revenue. Veracyte assumes collection risk. In FY2025, Medicare represented 33% of company revenue and UnitedHealthcare 14%. Within testing revenue, Medicare fee-for-service was 34%, Medicare Advantage 18%, Medicaid 1%, and private commercial payers 47%. Evidence, coding, coverage, pricing, and claims collection therefore matter as much as laboratory science. The 2025 Form 10-K provides the payer detail.

How does a test become a durable revenue stream?

Which tests matter most to Veracyte's growth?

Decipher Prostate is the largest franchise

Decipher Prostate uses whole-transcriptome analysis and machine learning to estimate metastatic risk and guide treatment across prostate cancer. Q1 2026 revenue grew 30% to $86.5 million and volume rose 24% to about 28,000 tests—roughly 62% of company revenue. Veracyte reports more than 115 peer-reviewed studies and payer coverage representing over 215 million enrollees.

Afirma supplies a second scaled growth engine

Afirma classifies indeterminate thyroid nodules to identify patients who may avoid diagnostic surgery. Q1 2026 revenue increased 21% to $46.4 million and volume rose 12% to about 17,200 tests. Veracyte reports more than 160 peer-reviewed studies and coverage for over 275 million enrollees. Decipher and Afirma together generated $132.9 million in Q1 2026.

What did Veracyte's latest quarter show?

For the quarter ended March 31, 2026, revenue rose 21% to $139.1 million and testing revenue rose 26% to $135.1 million. Total volume increased 17% to 47,615 tests; testing volume increased 19% to 45,248. Gross profit reached $101.2 million and GAAP gross margin expanded to 72.7% from 69.5%. Operating expenses rose only 2.5%, so operating income increased to $22.6 million from $2.9 million.

Why did profitability improve so quickly?

Gross profit grew 27% while operating expense grew about 2%. R&D increased to $27.1 million, but general and administrative expense fell to $23.7 million. GAAP operating margin reached 16.3%, net margin 20.6%, and adjusted EBITDA $42.8 million, or 30.8% of revenue. Management raised 2026 revenue guidance to $582 million-$592 million and adjusted EBITDA margin guidance above 26%. See the earnings release and Form 10-Q.

How did Veracyte become a scaled cancer-diagnostics platform?

Veracyte combined organic evidence generation with acquisitions that added disease areas, commercial teams, manufacturing, and monitoring technology. This history explains both the portfolio breadth and the large goodwill balance.

1. 2008
   Founded around using genomic classifiers to resolve uncertain cancer decisions, initially in thyroid disease.
2. 2011-2013
   Afirma commercialization and the 2013 IPO funded evidence, reimbursement, and specialist sales.
3. 2019
   Acquired NanoString diagnostics assets for $40.0M, adding Prosigna and an international IVD channel.
4. 2021
   Acquired Decipher Biosciences for $600M, adding today’s largest franchise.
5. 2021
   Acquired HalioDx for €260M; later restructuring exposed global-execution risk.
6. 2024
   Acquired C2i for $70M upfront plus up to $25M, adding whole-genome MRD technology.
7. 2025-2026
   Deconsolidated Veracyte SAS and prioritized U.S. testing, Prosigna LDT, and TrueMRD.

What did the acquisition strategy achieve?

Decipher transformed scale; the transaction announcement emphasized growth and market expansion. C2i added whole-genome MRD through a mostly equity-funded deal, as shown in the acquisition disclosure. The trade-off appears in Q1 2026 goodwill of $767.2 million and intangibles of $85.9 million: successful launches support the investment; underperformance can cause impairment.

What gives Veracyte a competitive advantage?

Evidence, coverage, and specialist workflow create the moat

A molecular test becomes defensible only after it produces reproducible results, changes clinical decisions, earns guideline support, and obtains payer coverage. Veracyte reports more than 600 peer-reviewed publications. Decipher’s guideline position and Afirma’s broad coverage create switching friction because challengers must alter established physician and payer workflows.

The Veracyte Diagnostics Platform adds a data flywheel: whole-omic profiling expands a genomic and clinical database that can support new classifiers, evidence, and indications. Samples, outcomes, specialist relationships, reimbursement expertise, and laboratory operations are harder to reproduce than a single patent.

Where is the moat still unproven?

The moat is strongest in established franchises and less proven in breast-cancer LDTs and MRD. Prosigna LDT faces Exact Sciences, Myriad, and Agendia; TrueMRD faces Natera and a broad liquid-biopsy field. Platform reuse lowers launch friction but cannot replace indication-specific evidence and reimbursement.

Where does competition come from?

Afirma competes with ThyroSeq and Interpace; Decipher with Myriad, MDxHealth, clinical nomograms, and AI-enabled pathology such as ArteraAI. MRD competition includes Natera, Guardant Health, Exact Sciences, Personalis, Tempus AI, and large reference laboratories. Veracyte is therefore a focused leader in selected clinical questions, not a category-wide monopoly.

How financially strong is Veracyte?

FY2025 revenue increased 16% to $517.1 million, gross profit rose 22% to $362.5 million, operating income reached $57.8 million, and net income reached $66.4 million. Operating cash flow was $136.3 million and property-and-equipment purchases were $9.7 million, implying about $126.6 million of simple free cash flow before acquisitions and other investing activity.

What does the balance sheet allow management to do?

Liquidity can fund launches, studies, automation, sales expansion, and acquisitions without immediate debt dependence. Yet investors should compare those uses with dilution and acquisition returns. Stock-based compensation was $12.8 million in Q1 2026, and C2i was largely equity-financed.

Who owns Veracyte stock, and why does governance matter?

Veracyte has one class of common stock rather than founder super-voting shares. The 2026 proxy reports BlackRock at 15.0%, Artisan Partners 7.8%, FMR 7.1%, and State Street 5.3%. Directors and executive officers collectively owned 1.6%. Large institutions therefore have meaningful voting influence, while management cannot unilaterally control strategy.

How are management incentives structured?

The nine-member board uses ownership guidelines of three times base salary for the CEO, one times salary for other C-level executives, and three times annual cash retainer for non-employee directors. Anti-hedging and anti-pledging rules reinforce exposure to long-term outcomes. See the 2026 proxy statement.

What opportunities and risks could change Veracyte's outlook?

The next growth leg depends on launches, not just core volume

Core growth comes from Decipher and Afirma, while diversification depends on Prosigna LDT, TrueMRD, and Percepta Nasal Swab. Prosigna could expand U.S. breast testing; TrueMRD could create serial monitoring revenue; Percepta could address the lung-nodule diagnostic funnel. Each still requires evidence, coverage, workflow adoption, and disciplined launch spending.

Which risks are most material?

• Reimbursement: coverage, coding, rates, denials, and collections directly affect revenue; 2026 PAMA reporting may influence 2027 Medicare rates.
• Regulation: the FDA LDT rule was vacated, but legislation or future regulation could add review costs or delay launches.
• Concentration: Decipher and Afirma generated about 95.5% of Q1 2026 revenue.
• Launch execution: Prosigna LDT, TrueMRD, and Percepta need evidence, coverage, and physician adoption.
• Technology and acquisitions: digital pathology, alternative MRD methods, cybersecurity, dilution, or impairment could reduce returns.

Why does Veracyte's business model matter for valuation?

A valuation should separate scaled franchises from probability-weighted pipeline assets. Decipher and Afirma have observable volume, reimbursement, costs, and commercial spending. Prosigna LDT, TrueMRD, and Percepta carry greater uncertainty around launch timing, adoption, pricing, and market share.

Which DCF drivers deserve the most attention?

The key DCF inputs are franchise volume, realized revenue per test, payer mix, gross margin, operating-expense discipline, and reinvestment. New assays may initially run at inefficient batch sizes. Terminal assumptions should reflect reimbursement and technology risk rather than drug-like patent exclusivity.

What is the key takeaway from Veracyte analysis?

Veracyte is no longer only a speculative diagnostics developer. FY2025 and Q1 2026 showed scaled revenue, GAAP profitability, operating cash flow, and strong liquidity. Decipher and Afirma combine specialist adoption, evidence, coverage, and laboratory scale, funding investment in Prosigna LDT, TrueMRD, and Percepta.

The tension is concentration versus expansion. Two franchises produced about 95.5% of Q1 2026 revenue, exposing Veracyte to payer and competitive risk. New tests can diversify revenue, but they enter established markets and require years of evidence. The balance sheet lowers financing risk; $853.0 million of goodwill and intangibles keeps acquisition returns central.